<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> white women have lower rates of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening compared to non-<z:mp ids='MP_0001261'>obese</z:mp> women </plain></SENT>
<SENT sid="1" pm="."><plain>This study will determine if a relationship exists between weight and adherence to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening guidelines among African Americans </plain></SENT>
<SENT sid="2" pm="."><plain>We used multivariate logistic regression to examine the relationship between being up-to-date with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening (colorectal, breast, cervical, and prostate) and weight group (<z:mpath ids='MPATH_458'>normal</z:mpath>, overweight, <z:mp ids='MP_0001261'>obese</z:mp> I, <z:mp ids='MP_0001261'>obese</z:mp> II+) using data from older (age 50+) members (N = 955) of 20 African American churches in Michigan and North Carolina </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> testing rates were examined using multiple definitions to account for differences in screening rates vs. <z:mpath ids='MPATH_491'>polyp</z:mpath> surveillance rates </plain></SENT>
<SENT sid="4" pm="."><plain>After adjusting for confounders, we found relationships between weight group and up-to-date <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (P = 0.04) and PSA (P = 0.004) testing for men and mammography (P = 0.03) for women </plain></SENT>
<SENT sid="5" pm="."><plain>Compared to <z:mpath ids='MPATH_458'>normal</z:mpath>-weight men, <z:mp ids='MP_0001261'>obese</z:mp> I men were more likely to be up-to-date with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (OR 2.35, 95%CI 1.02-5.40) and PSA (OR 4.24 95%CI 1.77-10.17) testing </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening rates were lower when individuals with <z:mpath ids='MPATH_491'>polyps</z:mpath> were excluded from the analysis; however, patterns by weight remained the same </plain></SENT>
<SENT sid="7" pm="."><plain>Contrary to previous research, we did not find lower rates of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening among <z:mp ids='MP_0001261'>obese</z:mp> African Americans </plain></SENT>
<SENT sid="8" pm="."><plain>Instead, we found that <z:mpath ids='MPATH_458'>normal</z:mpath>-weight African American men had lower screening rates than any other group </plain></SENT>
<SENT sid="9" pm="."><plain>As we did not consistently find lower screening rates among <z:mp ids='MP_0001261'>obese</z:mp> African Americans, targeting this group for increased screening promotion may not be the most effective way to reduce weight-related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> disparities </plain></SENT>
</text></document>